106.43
+0.03(+0.03%)
Currency In USD
Address
3 More London Riverside
London, SE1 2RE
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 3283 4200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
209
First IPO Date
April 28, 2017
| Name | Title | Pay | Year Born |
| Dr. David S. Zaccardelli Pharm.D. | President, Chief Executive Officer & Executive Director | 1.37M | 1964 |
| Mr. Andrew Fisher | General Counsel | 596,932 | 1970 |
| Dr. Kathleen A. Rickard M.D. | Chief Medical Officer | 726,000 | 1958 |
| Mr. Mark W. Hahn | Chief Financial Officer | 915,915 | 1963 |
| Mr. Matthew Casbon | Vice President of Sales, Marketing & Training | 0 | N/A |
| Dr. Tara Rheault M.P.H., Ph.D. | Chief Development Officer | 0 | 1976 |
| Mr. Christopher Martin | Chief Commercial Officer | 0 | N/A |
| Ms. Caroline Diaz | Chief Regulatory Officer | 0 | N/A |
| Ms. Victoria Stewart | Senior Director of Investor Relations & Communications | 0 | N/A |
| Ms. Ostra Jewell | Senior Vice President of Human Resources | 0 | N/A |
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.